AstraZeneca and IMS Health announce real-world evidence collaboration in Europe
- Details
- Category: AstraZeneca
AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.
A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health
- Details
- Category: Pfizer
Millions of resolutions come with every New Year, many of which are to get healthy. But, there's a lot of confusion around what constitutes healthy nutrition, which is a key piece of the puzzle.
Bayer HealthCare to Share Lab Space with Start-Up Companies
- Details
- Category: Bayer
One year after the opening of its U.S. Innovation Center, Bayer HealthCare is expanding its U.S. research model. The company will open the CoLaborator™ - a 550 square meter shared lab for start-up life science companies whose technology platforms, drug targets or drug candidates align with Bayer's portfolio.
AstraZeneca reaffirms December 2011 financial guidance for 2011
- Details
- Category: AstraZeneca
During a routine consensus collection process, confidential Company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community that follows the Company.
Bristol-Myers Squibb to Acquire Inhibitex
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.
Pfizer Receives FDA Approval to Extend Use of Prevnar 13®
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.
Boehringer Ingelheim significantly expands its supply center for China
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai into a strategically important supply center for China. The goal of this project is to bring more health to more patients and to continuously improve Boehringer Ingelheim's product competitiveness and enlarge its market share.
More Pharma News ...
- First-of-its-kind endovascular trial of the investigational Esprit(TM) therapy
- GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
- AstraZeneca updates on olaparib and TC-5214 development programmes
- Four potential blockbusters in the Pharma pipeline
- Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars
- Prevent Pneumococcal Disease in Infants and Young Children in the World's Poorest Countries
- Simcere and Bristol-Myers Squibb Enter Innovative Partnership